Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer - 16/01/22
pages | 20 |
Iconographies | 11 |
Vidéos | 0 |
Autres | 0 |
Abstract |
Breast carcinomas repeat their number and grow exponentially making it extremely frequent malignancy among women. Approximately, 70–80% of early diagnosed or non-metastatic conditions are treatable while the metastatic cases are considered ineffective to treat with current ample amount of therapy. Target based anti-cancer treatment has been in the limelight for decades and is perceived significant consideration of scientists. Aptamers are the ‘coming of age’ therapeutic approach, selected using an appropriate tool from the library of sequences. Aptamers are non-immunogenic, stable, and high-affinity ligand which are poised to reach the clinical benchmark. With the heed in nanoparticle application, the delivery of aptamer to the specific site could be enhanced which also protects them from nuclease degradation. Moreover, nanoparticles due to robust structure, high drug entrapment, and modifiable release of cargo could serve as a successful candidate in the treatment of breast carcinoma. This review would showcase the method and modified method of selection of aptamers, aptamers that were able to make its way towards clinical trial and their targetability and selectivity towards breast cancers. The appropriate usage of aptamer-based biosensor in breast cancer diagnosis have also been discussed.
Le texte complet de cet article est disponible en PDF.Graphical Abstract |
Highlights |
• | Aptamers are single stranded oligonucleotides. |
• | MUC1, EpCAM along with other receptor are overexpressed in breast cancer cells. |
• | Aptamer bind to the target cell with high affinity and specificity. |
• | Aptasensor can detect cancer at early stage. |
Keywords : Breast cancer, Aptamer, Nanoparticle, Aptasensor, Biosensor, SELEX, Chemotherapy, targeted therapy, Nanomedicine, siRNA
Plan
Vol 146
Article 112530- février 2022 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?